Dr. Luke Nordquist

chemotherapy treatment "This is a new and intriguing approach to treating very sick prostate cancer patients," said Luke Nordquist, M.D., the principal investigator for the study at Methodist Estabrook Cancer Center."Results from large initial studies have shown that ASENTAR appeared to improve survival while reducing some of the serious side effects of the chemotherapy.This was somewhat of a surprising result that deservesfurther clinical evaluation."Dr. Nordquist noted that the Phase 3 clinical study is designed to determine if